Literature DB >> 14723003

Radiation sensitizers and targeted therapies.

Theodore S Lawrence1.   

Abstract

Chemotherapeutic agents that are highly responsive to ionizing radiation and enhance the effectiveness of radiation treatment are termed radiation sensitizers. Radiation sensitizers act in a number of ways to make cancer cells more susceptible to death by radiation than surrounding normal cells, and several such compounds are now available for the treatment of solid tumors. This review discusses the biology that underlies chemotherapy and radiation interactions for one radiosensitizer--gemcitabine (Gemzar). It also provides a brief assessment of how to modify treatment regimens for various cancers to maximize the radiosensitization potential of gemcitabine in order to further increase efficacy. Newer molecularly targeted agents and their antitumor potential as monotherapy or in combination with radiation are also reviewed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14723003

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  7 in total

1.  Gold-containing indoles as anticancer agents that potentiate the cytotoxic effects of ionizing radiation.

Authors:  Sandra Craig; Lei Gao; Irene Lee; Thomas Gray; Anthony J Berdis
Journal:  J Med Chem       Date:  2012-02-15       Impact factor: 7.446

Review 2.  Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.

Authors:  Charles A Kunos; Tomas Radivoyevitch; Stephen T Ingalls; Charles L Hoppel
Journal:  Future Oncol       Date:  2012-02       Impact factor: 3.404

3.  Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma.

Authors:  R Krempien; M W Muenter; W Harms; J Debus
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

4.  Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

Authors:  R Krempien; M W Muenter; P E Huber; S Nill; H Friess; C Timke; B Didinger; P Buechler; S Heeger; K K Herfarth; A Abdollahi; M W Buchler; J Debus
Journal:  BMC Cancer       Date:  2005-10-11       Impact factor: 4.430

5.  Reducing X-Ray Induced Oxidative Damages in Fibroblasts with Graphene Oxide.

Authors:  Yong Qiao; Peipei Zhang; Chaoming Wang; Liyuan Ma; Ming Su
Journal:  Nanomaterials (Basel)       Date:  2014       Impact factor: 5.076

6.  Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib.

Authors:  Kyle C Cuneo; Ranjit K Mehta; Himabindu Kurapati; Dafydd G Thomas; Theodore S Lawrence; Mukesh K Nyati
Journal:  Transl Oncol       Date:  2018-11-06       Impact factor: 4.243

7.  Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells.

Authors:  Marilena Celano; Maria Grazia Calvagno; Stefania Bulotta; Donatella Paolino; Franco Arturi; Domenicoantonio Rotiroti; Sebastiano Filetti; Massimo Fresta; Diego Russo
Journal:  BMC Cancer       Date:  2004-09-13       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.